Hypothyroidism Associated With Aminoglutethimide in Patients With Prostate Cancer

William D. Figg, Alain Thibault, A. Oliver Sartor, David Mays, Donna Headlee, Karim A. Calis, Michael R. Cooper

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Objective: The administration of aminoglutethimide and hydrocortisone is a second-line hormonal maneuver commonly prescribed for the treatment of metastatic prostate cancer. We determine the incidence of aminoglutethimide-induced primary hypothyroidism in an elderly population who have prostate cancer. Design: Prospective evaluation. Patients: Twenty-nine men with stage D2 prostate cancer who were treated at the National Cancer Institute, Bethesda, Md, in 1992. Results: Clinical and biochemical evidence of hypothyroidism (thyrotropin levels greater than 10 mU/L) was noted in nine of 29 patients treated following the initiation of aminoglutethimide (250 mg four times daily). The elevation in thyrotropin and the clinical symptoms of hypothyroidism were reversed by the administration of levothyroxine (n=4). Conclusion: Hypothyroidism should be included in the differential diagnosis of lethargy in elderly patients who are receiving aminoglutethimide for prostate cancer. Furthermore, patients who are receiving this agent at a dosage of 1000 mg/d or greater should have their serum thyrotropin levels monitored, and replacement therapy with levothyroxine should be initiated when abnormally elevated levels are noted.

Original languageEnglish
Pages (from-to)1023-1025
Number of pages3
JournalArchives of Internal Medicine
Issue number9
StatePublished - 9 May 1994
Externally publishedYes


Dive into the research topics of 'Hypothyroidism Associated With Aminoglutethimide in Patients With Prostate Cancer'. Together they form a unique fingerprint.

Cite this